114 related articles for article (PubMed ID: 20508304)
1. Histo-morpho-biochemical findings of the residual prostate (III): (undetectable) PSA maintained after retropubic adenomectomy for BPH.
Ballesteros Sampol JJ; Gimeno Beltrán J; Fumadó Ciutat L
Arch Esp Urol; 2010 May; 63(4):282-6. PubMed ID: 20508304
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
3. [Biochemical-histo-morphometric findings of the residual prostate (II): long-term PSA behavior after retropubic adenomectomy for BPH. Relationship with prostate volume, histology and its implications in the diagnosis of subsequent adenocarcinoma].
Ballesteros Sampol JJ; Lloreta Trull J; Fumadó Ciutat L
Arch Esp Urol; 2009 Nov; 62(9):713-8. PubMed ID: 19955595
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
Marks LS; Dorey FJ; Rhodes T; Shery ED; Rittenhouse H; Partin AW; deKernion JB
J Urol; 1996 Sep; 156(3):1035-9. PubMed ID: 8709302
[TBL] [Abstract][Full Text] [Related]
5. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
Semjonow A; Hamm M; Rathert P
Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
[TBL] [Abstract][Full Text] [Related]
6. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
7. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
8. Reference range of prostate-specific antigen after transurethral resection of the prostate.
Aus G; Bergdahl S; Frösing R; Lodding P; Pileblad E; Hugosson J
Urology; 1996 Apr; 47(4):529-31. PubMed ID: 8638362
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
10. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
12. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
[TBL] [Abstract][Full Text] [Related]
13. [Impact of prostatic benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels].
Ferrero Doria R; Pérez Flores D; Terrer Artes C; Guzmán Martínez-Valls PL; Morga Egea JP; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Fontana Compiano LO
Actas Urol Esp; 1997 Feb; 21(2):100-4. PubMed ID: 9214204
[TBL] [Abstract][Full Text] [Related]
14. [Prostate cancer after prostatectomy for benign prostatic hyperplasia].
Hua L; Zhang J; Wu H; Sui Y; Zhang W; Qian L; Wang Z
Zhonghua Nan Ke Xue; 2004 Aug; 10(8):612-3. PubMed ID: 15362527
[TBL] [Abstract][Full Text] [Related]
15. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen.
Song L; Zhu Y; Han P; Chen N; Lin D; Lai J; Wei Q
Urology; 2011 Mar; 77(3):688-92. PubMed ID: 20974483
[TBL] [Abstract][Full Text] [Related]
17. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
[TBL] [Abstract][Full Text] [Related]
18. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
19. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
20. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
